BSC
CORT icon

BOLTON SECURITIES CORPORATION’s Corcept Therapeutics CORT Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Buy
+12,000
New +$449K 0.02% 562
2025
Q1 		$602K Buy
+5,270
New +$321K 0.04% 437

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's CORT Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 12,000 shares worth $484K. The stake represents 0.02% of the portfolio and ranks #562 among its holdings. This is a return to the name: BOLTON SECURITIES CORPORATION previously reported a position in CORT as recently as Q1 2025.

BOLTON SECURITIES CORPORATION first reported a position in CORT in Q1 2025 and has held it in 2 quarters since. The position peaked at $602K in Q1 2025. 353 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • BOLTON SECURITIES CORPORATION held 12,000 shares of Corcept Therapeutics worth $484K as of Q1 2026.
  • Corcept Therapeutics was a new BOLTON SECURITIES CORPORATION position in Q1 2026.
  • Corcept Therapeutics made up 0.02% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2026, its #562 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • BOLTON SECURITIES CORPORATION's Corcept Therapeutics position peaked at $602K in Q1 2025.
  • 353 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.